NCT03678883 2026-04-039-ING-41 in Patients With Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT05824975 2024-11-25A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)GI Innovation, Inc.Phase 1/2 Recruiting358 enrolled
NCT01992341 2014-09-23AMG 386 Drug-Drug Interaction Study With PaclitaxelAmgenPhase 1 Completed35 enrolled